Medpace Holdings, Inc. (MEDP)
| Market Cap | 17.33B +33.5% |
| Revenue (ttm) | 2.78B +24.7% |
| Net Income | 491.50M +17.5% |
| EPS | 17.06 +26.8% |
| Shares Out | 27.91M |
| PE Ratio | 36.39 |
| Forward PE | 33.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,396 |
| Open | 614.13 |
| Previous Close | 612.64 |
| Day's Range | 600.01 - 629.69 |
| 52-Week Range | 373.00 - 677.90 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 581.83 (-6.27%) |
| Earnings Date | Jul 22, 2026 |
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man... [Read more]
Financial Performance
In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MEDP stock is "Hold." The 12-month stock price target is $581.83, which is a decrease of -6.27% from the latest price.
News
Medpace price target raised to $692 from $484 at RBC Capital
RBC Capital analyst Ryan Halsted raised the firm’s price target on Medpace (MEDP) to $692 from $484 and keeps an Outperform rating on the shares. The company’s Q2 results represent…
Medpace price target raised to $665 from $586 at Mizuho
Mizuho raised the firm’s price target on Medpace (MEDP) to $665 from $586 and keeps an Outperform rating on the shares. The firm sees improving bookings visibility post the company’s…
Medpace price target raised to $600 from $400 at BMO Capital
BMO Capital raised the firm’s price target on Medpace (MEDP) to $600 from $400 and keeps a Market Perform rating on the shares. The revenue mix continues to shift from…
Medpace price target raised to $492 from $419 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Medpace (MEDP) to $492 from $419 and keeps a Hold rating on the shares. The firm thinks the company’s…
Medpace price target raised to $624 from $547 at Baird
Baird raised the firm’s price target on Medpace (MEDP) to $624 from $547 and keeps a Neutral rating on the shares.
Medpace price target raised to $620 from $515 at Leerink
Leerink raised the firm’s price target on Medpace (MEDP) to $620 from $515 and keeps a Market Perform rating on the shares.
Medpace price target raised to $600 from $450 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $600 from $450 and keeps an Equal Weight rating on the shares. The firm updated the company’s…
Medpace price target raised to $535 from $480 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Medpace (MEDP) to $535 from $480 and keeps a Hold rating on the shares.
Medpace Holdings Earnings Call Transcript: Q2 2026
Q2 2026 delivered strong revenue and net income growth, with record net bookings and a robust business environment. Oncology bookings surged, cancellations declined, and guidance for 2026 was raised, projecting double-digit growth in revenue and EBITDA.
Medpace Holdings Earnings release: Q2 2026
Medpace Holdings released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Medpace Holdings Slides: Q2 2026
Medpace Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Medpace Holdings Quarterly report: Q2 2026
Medpace Holdings has published its Q2 2026 quarterly earnings report on July 23, 2026.
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Reven...
Medpace price target raised to $586 from $495 at Mizuho
Mizuho raised the firm’s price target on Medpace (MEDP) to $586 from $495 and keeps an Outperform rating on the shares. The firm adjusted targets in the healthcare facilities and…
Medpace downgraded to Neutral from Outperform at Baird
Baird analyst Eric Coldwell downgraded Medpace (MEDP) to Neutral from Outperform with a price target of $547, up from $477. not While “not worried” about 2026 guidance, the analyst says…
Medpace downgraded to Hold from Buy at Jefferies
Jefferies downgraded Medpace (MEDP) to Hold from Buy with a price target of $515, up from $490. The firm cites a growing disconnect between valuation and achievable growth for the…
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 2...
MEDP Fraud Notice: Medpace Sued for Securities Fraud after 16% Stock Drop -- Investors Reminded to Contact BFA Law by June 8 Case Deadline
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ:MEDP) and ...
Medpace Lawsuit Reminder: Investors with Losses after Company Discloses Cancellation Rates are Urged to Contact BFA Law before June 8 Deadline - NASDAQ:MEDP
NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ:MEDP) and ...
MEDP Fraud News: Medpace Sued for Securities Fraud Over Cancellation Rates and 16% Stock Drop – Contact BFA Law if You Lost Money
NEW YORK--(BUSINESS WIRE)---- $MEDP #BFA--Medpace Sued for Securities Fraud Over Cancellation Rates and 16% Stock Drop – Contact BFA Law if You Lost Money.
Medpace price target lowered to $400 from $460 at BMO Capital
BMO Capital lowered the firm’s price target on Medpace (MEDP) to $400 from $460 and keeps a Market Perform rating on the shares. The company’s results were well ahead of…
Medpace price target lowered to $484 from $522 at RBC Capital
RBC Capital analyst Ryan Halsted lowered the firm’s price target on Medpace (MEDP) to $484 from $522 and keeps an Outperform rating on the shares after its Q1 results and…
Medpace Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 26.5% revenue growth and strong new business awards, but elevated cancellations and weaker gross bookings led to a net book-to-bill of 0.88. Guidance remains unchanged, with management focused on improving win rates and expanding the pipeline.